FREE SHIPPING ON ORDERS OVER $200 Now testing for heavy metals and endotoxins ≥98.5% purity Third-party HPLC tested COA on every batch Fast, discreet US shipping
5-Amino-1MQ 5mg research peptide vial
Metabolic

5-Amino-1MQ

Small-molecule NNMT inhibitor studied in metabolic and adipocyte research.

From $120

In stock · ships in 1–2 business days

  • ✓ ≥98.5% purity
  • ✓ HPLC + mass-spec tested
  • ✓ Batch COA available
  • ✓ Discreet US shipping
NNMTmetabolic research

Research Summary

5-Amino-1MQ is a small molecule investigated in preclinical research as an inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme studied in adipose-tissue energy metabolism. It is of interest to researchers examining cellular NAD+ salvage and metabolic regulation. For laboratory research use only.

Handling

Store the sealed lyophilized peptide at -20°C, protected from light and moisture. Let the vial reach room temperature before opening to limit condensation. Any further handling should follow your laboratory's own validated procedures, using appropriate protective equipment.

Research overview

5-Amino-1MQ: what the research shows

Reviewed October 12, 2026 against PubMed and primary sources. For research context only, not medical advice.

What is 5-Amino-1MQ?

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small organic molecule, not a peptide. Its core is a quinoline ring carrying a methyl group on the ring nitrogen, which gives the molecule a permanent positive charge, and an amino group at position 5 [1]. As a charged species it is usually handled as a salt; PubChem holds a separate record for the iodide salt [2].

The compound comes from a medicinal-chemistry program at the University of Texas Medical Branch that searched for inhibitors of nicotinamide N-methyltransferase (NNMT). In a 2017 structure-activity study, the group screened N-methylated quinolinium, isoquinolinium, pyridinium, and benzimidazolium or benzothiazolium analogues and identified quinoliniums as the most promising scaffold, with NNMT inhibition in the low micromolar range (IC50 of about 1 µM) [3]. Different papers abbreviate the compound as 5A1MQ, 5MQ, or 5-AMQ [4] [5] [6].

It is listed in our metabolic research category, alongside peptides studied in related energy-metabolism models such as AOD-9604.

5-Amino-1MQ molecular identity
Chemical name5-amino-1-methylquinolinium (IUPAC: 1-methylquinolin-1-ium-5-amine)
Compound classSmall molecule (quaternary methylquinolinium), not a peptide
Molecular formulaC10H11N2+ (cation); C10H11IN2 (iodide salt)
Molecular weight159.21 g/mol (cation); 286.11 g/mol (iodide salt)
CAS number685079-15-6 (cation); 42464-96-0 (iodide salt)
PubChem CID950107 (cation); 66522933 (iodide salt)
Other names5-Amino-1MQ, 5A1MQ, 5MQ, 5-AMQ, NNMTi

The NNMT enzyme

NNMT is a cytosolic enzyme that transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide, a form of vitamin B3 and a precursor of NAD+. A 2014 study in mice identified Nnmt as the gene most strongly and reciprocally regulated in white adipose tissue when comparing mice that lacked or overexpressed the Glut4 glucose transporter in fat. NNMT expression was increased in the adipose tissue and liver of obese and diabetic mice, and knocking down Nnmt in fat and liver protected the animals against diet-induced obesity by increasing cellular energy expenditure. Reduced NNMT activity raised adipose SAM and NAD+ levels and increased polyamine flux, linked to effects on histone methylation [7].

That work established NNMT as a research target in metabolism and prompted the search for small-molecule inhibitors, of which 5-amino-1MQ is one.

Mechanisms studied

Binding at the nicotinamide site

In the 2017 study, computer docking placed the quinolinium inhibitors in the enzyme's substrate (nicotinamide) binding site, and docking scores correlated with the measured IC50 values [3].

Permeability and selectivity

A 2018 follow-up characterized a series of methylquinolinium NNMT inhibitors. Analogues with primary amine substitutions showed high permeability in parallel artificial membrane and Caco-2 cell assays. The compounds did not inhibit structurally related SAM-dependent methyltransferases or enzymes of the NAD+ salvage pathway [8].

Effects in cultured adipocytes

In cultured adipocytes, the same inhibitors reduced intracellular 1-methylnicotinamide (the product of the NNMT reaction), increased intracellular NAD+ and SAM, and suppressed lipogenesis [8].

Areas of research

Diet-induced obesity models in mice

The 2018 study reported that a potent methylquinolinium NNMT inhibitor reduced body weight, white adipose mass, adipocyte size, and plasma total cholesterol in diet-induced obese mice, without changing total food intake [8]. A 2024 study that names the compound as 5A1MQ found that it limited gains in body weight and fat mass, improved oral glucose tolerance and insulin sensitivity, and attenuated hepatic steatosis and macrophage infiltration in diet-induced obese mice. The same paper characterized its plasma pharmacokinetics and reported distribution to adipose tissue, muscle, and liver [4].

A 2022 study gave 5-amino-1-methylquinolinium to diet-induced obese mice switched to a low-fat diet and examined their gut microbiome. Treated mice developed a distinct cecal microbiome pattern, with lower relative abundance of Erysipelatoclostridium and higher Lactobacillus than vehicle controls on the same diet [9].

Aged skeletal muscle

The originating group also studied an NNMT inhibitor in 24-month-old mice after an experimental muscle injury. Muscle stem cell proliferation and fusion were higher in treated mice, regenerating fibers had larger cross-sectional areas, and contractile function of the injured muscle was greater than in controls. In C2C12 myoblasts, the inhibitor promoted differentiation [10]. A 2024 study in aged mice reported greater grip strength with NNMT inhibition and additive effects when it was combined with exercise [11].

Cancer cell lines

Independent groups have tested 5-amino-1MQ in tumor cell lines, where NNMT is often overexpressed. In HeLa cervical cancer cells, 5-amino-1-methylquinolinium inhibited proliferation in a concentration- and time-dependent manner and produced morphological signs of apoptosis, without apparently affecting HEK-293 cell proliferation [5]. A 2025 study in osteosarcoma and Merkel cell carcinoma lines reported reduced viability, increased reactive oxygen species, and activation of apoptotic pathways with three NNMT inhibitors, including 5-amino-1-methyl quinolinium [6].

Kidney models

A 2026 study identified NNMT as a mediator of tubular senescence and kidney fibrosis, and reported that selective NNMT inhibition was protective in senescent kidney cells, kidney organoids, and mouse models [12]. The abstract does not name the specific inhibitor used.

A note on the evidence base

Most in vivo work on this compound comes from the group that developed it, and several of those papers declare that authors founded or are employed by a company developing NNMT inhibitors [4] [11]. Independent replication of the metabolic and muscle findings remains limited.

State of the human evidence

We found no published human studies of 5-amino-1MQ in PubMed as of this review. Everything summarized on this page comes from enzyme assays, cell culture, organoids, and mice. These findings should not be read as evidence of safety or benefit in people.

Regulatory status

Checked against primary sources on October 12, 2026.

  • Not FDA approved. No application for 5-amino-1-methylquinolinium appears in FDA's Drugs@FDA database of approved drug products [13].
  • Compounding. The compound does not appear on FDA's page of bulk drug substances that may present significant safety risks (content current as of April 22, 2026) [14].
  • Sport. The World Anti-Doping Agency's 2026 Prohibited List does not name 5-amino-1MQ. The list's examples are not exhaustive [15].

Rejuvatide supplies 5-Amino-1MQ strictly as a research chemical for in vitro and laboratory use. It is not sold for human or veterinary use.

Testing and quality

A hosted third-party certificate for 5-Amino-1MQ is not yet published on this site. Batch documentation can be requested through our COA library. Answers to common ordering questions are on our FAQ page.

Storage

5-Amino-1MQ ships as a dry solid in a sealed vial. For long-term storage, keep sealed vials at -20°C, protected from light and moisture, and allow a vial to reach room temperature before opening to limit condensation. Handling of any prepared solutions should follow your laboratory's own validated procedures.

5-Amino-1MQ FAQ

What is 5-Amino-1MQ?

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT), studied in cell and mouse models of metabolism, muscle, and cancer biology.

Is 5-Amino-1MQ a peptide?

No. It is a small quaternary quinolinium molecule with a molecular weight of about 159 g/mol for the cation, far smaller than a peptide.

What does NNMT do?

NNMT transfers a methyl group from S-adenosylmethionine to nicotinamide. Mouse studies linked its activity in fat and liver to NAD+ levels, SAM levels, and cellular energy expenditure.

Has 5-Amino-1MQ been studied in humans?

We found no published human studies as of October 2026. The available data come from enzyme assays, cell lines, organoids, and mice.

Is 5-Amino-1MQ FDA approved?

No. It is not an FDA-approved drug and is sold by Rejuvatide only as a research chemical.

Is 5-Amino-1MQ for human use?

No. Rejuvatide sells 5-Amino-1MQ for laboratory research use only. It is not for human or veterinary use, and nothing on this site is medical advice.

References

  1. PubChem. 5-Amino-1-methylquinolinium, Compound CID 950107. National Library of Medicine. Source
  2. PubChem. 5-Amino-1-methylquinolinium iodide, Compound CID 66522933. National Library of Medicine. Source
  3. Neelakantan H, Wang HY, Vance V, et al. J Med Chem. 2017;60(12):5015-5028. PubMed 28548833
  4. Babula JJ, Bui D, Stevenson HL, et al. Diabetes Obes Metab. 2024;26(11):5272-5282. PubMed 39161060
  5. Akar S, Duran T, Azzawri AA, et al. J Obstet Gynaecol. 2021;41(8):1240-1245. PubMed 33645410
  6. Pompei V, Cecati M, Serritelli EN, et al. Biomolecules. 2025;15(11). PubMed 41301471
  7. Kraus D, Yang Q, Kong D, et al. Nature. 2014;508(7495):258-62. PubMed 24717514
  8. Neelakantan H, Vance V, Wetzel MD, et al. Biochem Pharmacol. 2018;147:141-152. PubMed 29155147
  9. Dimet-Wiley A, Wu Q, Wiley JT, et al. Sci Rep. 2022;12(1):484. PubMed 35013352
  10. Neelakantan H, Brightwell CR, Graber TG, et al. Biochem Pharmacol. 2019;163:481-492. PubMed 30753815
  11. Dimet-Wiley AL, Latham CM, Brightwell CR, et al. Sci Rep. 2024;14(1):15554. PubMed 38969654
  12. Chanvillard L, Lantermans HC, Wall C, et al. Cell Rep. 2026;45(1):116823. PubMed 41543936
  13. U.S. Food and Drug Administration. Drugs@FDA: FDA-approved drugs (searched October 12, 2026). Source
  14. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). Source
  15. World Anti-Doping Agency. The 2026 Prohibited List (official text as published in Tractatenblad 2026, no. 25). Source